Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 27Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 3Multiple Myeloma 3Metastatic Castration-resistant Prostate Cancer 3Lymphoma, Non-Hodgkin 3Lymphoma 3Lymphoma, B-Cell 2Endometrial Neoplasms 2Breast Neoplasms 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomatitis 1Stomach Neoplasms 1Recurrence 1Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oral Ulcer 1Myasthenia Gravis 1Metastatic Castration-Resistant Prostate Cancer Patients 1Metastatic Castration-Resistant Prostate Cancer 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 27Cisplatin 24pembrolizumab 15durvalumab 12Fluorouracil 11Capecitabine 10Oxaliplatin 9Leucovorin 8Bevacizumab 7Carboplatin 5Paclitaxel 4Nivolumab 4Irinotecan 4Injections 4zanidatamab 3trametinib 3lenvatinib 3derazantinib 3atezolizumab 3Ramucirumab 3Docetaxel 3tremelimumab 2surufatinib 2pertuzumab 2gemcitabine-oxaliplatin regimen 2envafolimab 2Trastuzumab 2S 1 (combination) 2Itraconazole 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × Prednisolone × Clear all
NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡